Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tectonic Therapeutic (TECX) Income towards Parent Company (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Income towards Parent Company data on record, last reported at -$25.1 million in Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 58.3% to -$25.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.2 million, a 81.79% increase, with the full-year FY2025 number at -$1.0 million, up 98.2% from a year prior.
  • Income towards Parent Company reached -$25.1 million in Q1 2026 per TECX's latest filing, down from $53.9 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for TECX hit a ceiling of $53.9 million in Q4 2025 and a floor of -$29.8 million in Q1 2022.
  • A 5-year average of -$14.1 million and a median of -$17.7 million in 2024 define the central range for Income towards Parent Company.
  • Peak YoY movement for Income towards Parent Company: tumbled 76.24% in 2024, then skyrocketed 646.12% in 2025.
  • Tracing TECX's Income towards Parent Company over 5 years: stood at -$25.0 million in 2022, then skyrocketed by 62.92% to -$9.3 million in 2023, then fell by 6.46% to -$9.9 million in 2024, then surged by 646.12% to $53.9 million in 2025, then crashed by 146.6% to -$25.1 million in 2026.
  • Business Quant data shows Income towards Parent Company for TECX at -$25.1 million in Q1 2026, $53.9 million in Q4 2025, and -$19.0 million in Q3 2025.